Joint Force Pharmaceutical is a leading cross-border pharmaceutical platform, connecting premier Chinese manufacturers to India and global markets through deep regulatory expertise, established relationships, and almost three decades of operational excellence.
Founded in 1996 by Dr. Tarun Gupta, Joint Force Pharmaceutical Limited (JFPL) was established to bridge a critical gap in the global pharmaceutical supply chain — connecting China's world-class manufacturing capabilities to the Indian pharmaceutical market and beyond.
What began as a specialised trading operation has grown into a full-scale cross-border pharmaceutical platform with offices in Hong Kong, Singapore, India, and Dubai. Our deep-rooted manufacturer relationships, regulatory knowledge across multiple jurisdictions, and customer-first approach have made JFPL a trusted name in pharmaceutical sourcing and distribution.
Today, under the management of Dr. Gupta and his son, Sanchit, we serve Indian formulation manufacturers, multinational pharmaceutical companies, and institutional buyers across Asia — providing access to high-quality Active Pharmaceutical Ingredients, Key Starting Materials, and Advanced Intermediates from China's leading manufacturers.
From sourcing and supply chain management to regulatory support and market access — we provide end-to-end pharmaceutical trading solutions.
We source high-quality Active Pharmaceutical Ingredients from China's leading GMP-certified manufacturers, ensuring product quality, regulatory compliance, and reliable supply for our customers.
Deep expertise in India's CDSCO/DCGI regulatory framework, supporting API registration processes for foreign manufacturers and ensuring seamless market entry into India.
Established distribution relationships across India and Southeast Asia, enabling Chinese manufacturers to access new markets and Indian buyers to secure competitive, quality supply.
End-to-end logistics management including customs clearance, cold-chain handling, and trade finance support — ensuring smooth, timely delivery of pharmaceutical products across borders.
Facilitating contract manufacturing arrangements between Indian formulation companies and Chinese API producers — supporting customised production agreements with quality assurance built in.
Market insights, pricing intelligence, and competitor analysis across the China-India pharmaceutical corridor — helping customers make informed procurement and business development decisions.
Our strongest product segment — covering Cephalosporins, Penicillins, and specialty antibiotic APIs sourced from China's leading GMP-certified manufacturers. We supply sterile and non-sterile grades for injection and oral formulations.
Sterile-grade APIs and KSMs for critical care applications including injectable antibiotics, antifungals, and supportive care products for hospital settings.
Supporting India's vaccine manufacturing sector with a focus on Hepatitis A and Hepatitis E vaccines. Through our affiliated entity Urihk Pharmaceutical, we are proud to have been the first company to launch the Hepatitis E vaccine in India — a landmark milestone in the country's public health journey.
A comprehensive range of KSMs, advanced intermediates, and raw materials supporting API synthesis in India — a critical value-add for vertically integrated Indian manufacturers looking to de-risk their supply chains.
Four offices positioned at the nexus of the world's most dynamic pharmaceutical trade corridors.
Our founding office and global headquarters, established in 1996. Hong Kong serves as our primary hub for China-facing manufacturer relationships, procurement operations, and cross-border trade management across Asia and beyond.
Joint Force Pharmaceutical Pte. Ltd. manages Southeast Asian distribution, investor relations, and corporate administration for the group — serving as our gateway to ASEAN pharmaceutical markets and regional institutional buyers.
India is our largest end-market, with deep relationships across major pharma manufacturing clusters. Our affiliated entity Urihk Pharmaceutical further strengthens our presence in vaccines and critical care across the subcontinent.
Operating out of the Sharjah Airport International Free Zone (SAIF Zone), our MEA office manages distribution partnerships, regulatory filings, and commercial operations across the GCC and African markets — one of the world's fastest-growing pharmaceutical regions.
Direct relationships with Tier-1 Chinese API manufacturers built over two decades, ensuring priority allocation, competitive pricing, and first access to new products.
Deep knowledge of CDSCO/DCGI processes, ASEAN regulatory frameworks, and Chinese GMP standards — enabling seamless cross-border compliance and market entry support.
Proven logistics infrastructure, buffer inventory management, and multi-source strategies ensure supply continuity even during market disruptions or force majeure events.
Rigorous vendor qualification, CoA verification, and on-site factory audits. We only work with manufacturers who meet international GMP standards and our own quality benchmarks.
Offices in Hong Kong, Singapore, India, and Dubai providing seamless service across time zones and regulatory regimes — a single point of contact for complex cross-border needs.
We build relationships, not transactions. Our customer retention speaks for itself — many of our key accounts have been with JFPL for over a decade.
Whether you're a manufacturer looking to enter the Indian market, or a buyer seeking reliable pharmaceutical supply — we'd like to hear from you.